IP Library Granted Patent US 7,989,175
Granted Patent B2
US 7,989,175 · App. 12/232,141 · Granted Aug 2, 2011

Method of classifying human subjects having adolescent idiopathic scoliosis

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,989,175
App. No.
12/232,141
Granted
Aug 2, 2011
Kind
B2
Abstract

A method for classifying human subjects having adolescent idiopathic scoliosis (AIS) into AIS subgroups, comprising detecting an impairment in the melatonin-signaling pathway in a cell sample from the subject, wherein the impairment is detected by an accumulation of cyclic adenosine 5′-monophosphate (cAMP) in the cell sample as compared to a control sample in the presence of a known melatonin-signaling pathway agonist, wherein the results of the detection step enable the classification of the subject having AIS into an AIS subgroup.

Claims (9)

1. A method of classifying a human subject having adolescent idiopathic scoliosis (AIS) comprising: providing a cell sample isolated from the subject; detecting an impairment in melatonin-signaling pathway in the sample in the presence and in the absence of a known melatonin-signaling pathway agonist, wherein the impairment is detected by an accumulation of cyclic adenosine 5′-monophosphate (cAMP) in the cell sample as compared to that in a control cell sample whereby the results of the detecting step enables the classification of the subject having AIS in one AIS subgroup.

2. The method of claim 1 , further comprising a step of selecting a treatment for the subject based on the results of the detecting step.

3. The method of claim 1 , wherein said accumulation of cAMP is induced by a known activator of adenylyl cyclase, and wherein the impairment is detected by an inhibition of said accumulation by a known melatonin-signaling pathway agonist that is detectably reduced in the cell sample as compared to that obtained in a control cell.

4. The method of claim 3 , wherein said known activator of adenylyl cyclase is forskolin.

5. The method of claim 3 , wherein said known melatonin-signaling pathway agonist is melatonin.

6. The method of claim 1 , wherein said known melatonin-signaling pathway agonist is GTP.

7. The method of claim 1 , wherein said cells are selected from the group consisting of osteoblasts, osteoclasts, lymphocytes, monocytes and myoblasts.

8. The method of claim 1 , wherein said cells are blood cells.

9. The method of claim 1 , wherein said cells are lymphocytes.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Feb 23, 2014
From: SIGULER GUFF DISTRESSED OPPORTUNITIES FUND III, LP
To: PARADIGM SPINE, LLC; FOURTH DIMENSION SPINE, LLC
Reel/Frame 032275/0800 →
SECURITY AGREEMENT Recorded Jun 29, 2011
From: FOURTH DIMENSION SPINE, LLC; PARADIGM SPINE, LLC
To: SIGULER GUFF DISTRESSED OPPORTUNITIES FUND III, LP
Reel/Frame 026525/0228 →
NUNC PRO TUNC ASSIGNMENT Recorded Apr 7, 2011
From: MOREAU, ALAIN
To: HOPITAL SAINTE-JUSTINE
Reel/Frame 026092/0055 →